Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Greenwich Lifesciences Inc (GLSI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: GLSI (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit -15.59% | Avg. Invested days 32 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 134.34M USD | Price to earnings Ratio - | 1Y Target Price 38 |
Price to earnings Ratio - | 1Y Target Price 38 | ||
Volume (30-day avg) 32581 | Beta 3.32 | 52 Weeks Range 9.06 - 18.75 | Updated Date 04/1/2025 |
52 Weeks Range 9.06 - 18.75 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.76 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -89.85% | Return on Equity (TTM) -151.72% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 119577622 | Price to Sales(TTM) - |
Enterprise Value 119577622 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -21.23 | Shares Outstanding 13144700 | Shares Floating 5906944 |
Shares Outstanding 13144700 | Shares Floating 5906944 | ||
Percent Insiders 53.05 | Percent Institutions 9.1 |
Analyst Ratings
Rating 4 | Target Price 38 | Buy 1 | Strong Buy - |
Buy 1 | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Greenwich Lifesciences Inc
Company Overview
History and Background
Greenwich LifeSciences, Inc. (GLSI) is a biopharmaceutical company focused on the development of immunotherapy to prevent breast cancer recurrences. Founded in 2006, it's primary focus has been on developing GP2, a HER2/neu peptide-based immunotherapy.
Core Business Areas
- Immunotherapy Development: Focused on the development of GP2, an immunotherapy designed to prevent the recurrence of breast cancer in patients who have previously undergone surgery.
Leadership and Structure
The leadership team consists of Snehal Patel (CEO), Javad Aslanzadeh, PhD (Chief Scientific Officer) and several directors. The organizational structure is typical of a small, clinical-stage biopharmaceutical company.
Top Products and Market Share
Key Offerings
- GP2 Immunotherapy: GP2 is Greenwich LifeSciences' primary product. It is designed to prevent breast cancer recurrence in HER2/neu positive patients who have completed initial treatment. Currently in Phase III clinical trials. No market share or revenue as the product is not yet approved. Competitors would include any future therapies targeting HER2/neu positive breast cancer recurrence, although this preventive immunotherapy approach is relatively novel.
Market Dynamics
Industry Overview
The pharmaceutical industry is dynamic and highly competitive, with significant investments in research and development. Cancer immunotherapy is a rapidly growing field.
Positioning
Greenwich LifeSciences is positioned as a company specializing in a novel breast cancer immunotherapy. Their competitive advantage hinges on the success of their GP2 clinical trials.
Total Addressable Market (TAM)
The TAM for breast cancer recurrence prevention is substantial, potentially several billion dollars annually. GLSI's position depends on GP2's efficacy and approval. Current estimates depend on peak sales projections, which vary considerably based on trial outcomes.
Upturn SWOT Analysis
Strengths
- Novel Immunotherapy Approach
- Focused on Unmet Medical Need
- Promising Early Clinical Data
Weaknesses
- Single Product Pipeline
- High Dependence on Clinical Trial Outcomes
- Limited Financial Resources
- Small Company Size
Opportunities
- Positive Clinical Trial Results
- Partnerships with Larger Pharmaceutical Companies
- Expansion into Other Cancer Indications
- Fast Track or Breakthrough Therapy Designation
Threats
- Clinical Trial Failure
- Regulatory Hurdles
- Competition from Established Pharmaceutical Companies
- Funding Challenges
Competitors and Market Share
Key Competitors
- There are no direct competitors with an identical product offering
- SNY (Sanofi)
- PFE (Pfizer)
- NVS (Novartis)
Competitive Landscape
Greenwich LifeSciences is attempting to carve out a niche in breast cancer recurrence prevention with a novel immunotherapy. Success will depend on clinical trial outcomes and its ability to compete with established pharmaceutical companies, that may offer preventative drugs as well.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is minimal, as the company is pre-revenue. Growth is tied to advancing GP2 through clinical trials.
Future Projections: Future growth depends entirely on GP2's success. Analyst projections vary widely, contingent on trial outcomes and regulatory approval.
Recent Initiatives: Recent initiatives include completing Phase IIb trials and initiating Phase III trials for GP2.
Summary
Greenwich Lifesciences is a high-risk, high-reward biopharmaceutical company with a single product pipeline focused on preventing breast cancer recurrence. Its success hinges entirely on the outcome of its Phase III clinical trials for GP2. Positive results could lead to significant market potential, while failure could severely impact the company. Investors should carefully consider the inherent risks associated with clinical-stage biopharmaceutical companies.
Similar Companies
- AGEN
- NK
- CLVS
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10K, 10Q)
- Company Website
- Press Releases
- Analyst Reports (where available)
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor. Information is current as of the date of generation and is subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Greenwich Lifesciences Inc
Exchange NASDAQ | Headquaters Stafford, TX, United States | ||
IPO Launch date 2020-09-25 | CEO, CFO & Director Mr. Snehal S. Patel | ||
Sector Healthcare | Industry Biotechnology | Full time employees 3 | |
Full time employees 3 | |||
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.